Pulse Biosciences Presents European Feasibility Study Demonstrates Using Nano-PFA In Benign Thyroid Nodules Reduces Nodule Volume By Greater Than 50% And Provides Symptomatic Relief Within The First Month Of Treatment At the American Thyroid Association
Portfolio Pulse from Benzinga Newsdesk
Pulse Biosciences announced positive results from a European feasibility study using its nano-PFA technology to treat benign thyroid nodules, showing over 50% reduction in nodule volume and symptomatic relief within a month.
October 31, 2024 | 6:26 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Pulse Biosciences' nano-PFA technology demonstrated significant efficacy in reducing benign thyroid nodule size by over 50% and providing symptomatic relief within a month, as presented at the American Thyroid Association Annual Meeting.
The positive preliminary results from the feasibility study using nano-PFA technology are likely to boost investor confidence in Pulse Biosciences. The significant reduction in nodule size and symptomatic relief could lead to increased adoption of their technology, potentially driving up the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100